Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory follicular lymphoma (r/r FL). As ELARA is a single-arm trial, this study compares tisa-cel outcomes from the ELARA trial with usual care from a real-wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Salles, Gilles, Schuster, Stephen J., Dreyling, Martin, Fischer, Luca, Kuruvilla, John, Patten, Piers E.M., von Tresckow, Bastian, Smith, Sonali M., Jiménez-Ubieto, Ana, Davis, Keith L., Anjos, Carla, Chu, Jufen, Zhang, Jie, Lobetti Bodoni, Chiara, Thieblemont, Catherine, Fowler, Nathan H., Dickinson, Michael, Martínez-López, Joaquin, Wang, Yucai, Link, Brian K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649992/
https://www.ncbi.nlm.nih.gov/pubmed/35973192
http://dx.doi.org/10.1182/bloodadvances.2022008150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649992/
https://www.ncbi.nlm.nih.gov/pubmed/35973192
http://dx.doi.org/10.1182/bloodadvances.2022008150

Ejemplares similares